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 What are antibiotics and how are they affecting people in the United States?  
 
 
 
The first person to use the word antibiotic was Selman Waksman. He used it 
to describe any small molecule that was produced by a microbe and prevented the 
growth of other microbes. Thus many antibiotics such as penicillin, streptomycin, 
and tetracycline came to be. All three were developed between 1945 and 1955. One 
main difference between these antibiotics is how they are produced. A fungus 
produces penicillin, while soil bacteria produce streptomycin and tetracycline (1). 
There are currently 160 classes of antibiotics known to date, most being discovered 
between 1940 and 1960 (2). Although antibiotics have been used to treat infections, 
the problem is that many antibiotics first discovered have become ineffective due to 
the evolution of antibiotic resistance by human pathogens. 
In the United States alone, hospital-acquired infections afflict nearly 2 million 
people, and of the 2 million people affected, approximately 100,000 people will die 
per year (3). The reason for the high numbers may be due to the fact that 70% of the 
infections are resistant to at least one antibiotic. The number of antibiotic resistant 
strains has increased at a rapid rate. The number of antibiotic 2 
 
resistant strains in San Francisco County were almost doubled and sometimes 
tripled between 1997 and 1998 (CDC). Since this time the numbers have increase 
10-20% (4). This was an indication of a trend occurring nationwide (see Figure 1). 
As a result the CDC estimates the direct costs associated with hospital infections are 
as high as $45 billion dollars each year. Justifiably we can say that antibiotic 
resistance is a severe problem. 
 
 
Figure 1.  Representation of the increase in antibiotic resistance from 
1996 to 1999. 3 
 
Communication in Bacteria 
 
 
 
  For many years it was believed bacteria were populations of cells that 
worked independently. However it has been discovered recently that bacteria 
interact and communicate with each other. In fact bacteria produce secondary 
metabolites that respond to various chemicals in their environment. Some 
secondary metabolite groups have been identified as playing a part in the regulation 
of gene expression in a cell-density-dependent manner known as quorum sensing or 
cell-cell communication (5).  It is believed that this results from the formation and 
accumulation of signaling molecules. These signaling molecules, known as 
autoinducers, will lead to gene expression changes when they are bound to 
receptors on or in the bacterial cell at a threshold concentration. 
  There is no clear-cut explanation of how common it is for cell-cell signaling to 
occur between bacteria cells. However there are two main components of 
communication to take into consideration: the cost associated with signaling and the 
specificity of the information (5).  The problem is the signal produced and the 
mechanism necessary to bring about a response is not clear. For proteins, 
production and export of signals acts catalytically (5).  For this reason it is 4 
 
assumed that the cost is of top priority. It is believed that production is inversely 
proportional to production cost. With specificity it is about the amount of 
information going into the signal and seems to correlate to the cost of production 
(5). Bacteria, especially in the soil, form antibiotics. However, they are only 
produced when they are needed because they are costly to the cell. There are few 
pathogens in the soil, which led scientists to believe that antibiotics are not only 
being produced as killers, but as signaling molecules in the cell. 
 
 (1) What is antibiotic resistance? 
Antibiotics are not just bacterial weapons that fight competitors; they are 
also signaling molecules that can regulate the homeostasis of microbial 
communities. In fact antibiotics are hormesis.  Hormesis is a concept that was 
originally used to describe the effects of low doses of radiation as a means of killing 
molecules (6).  A broader usage of the term is to describe biological responses to 
environmental signals and stresses, which act as stimulants at lower doses and as 
inhibitors at higher doses. In much the same way antibiotics act as bacterial killers 
at a high concentration but can produce changes that help bacteria in nature at 
lower concentrations. 
 
The first issue to consider is how a bacterium becomes resistant to the 
antibiotics. Bacteria that carry an antibiotic resistance gene in the plasmid of the 
bacteria cell can become resistant to antibiotics. This gene can easily be transferred     5  5 
to the plasmid of another bacteria cell by horizontal gene transmission (Figure 2). 
Bacteria can modify, degrade the antibiotics, or with the help of an efflux pump, 
remove the antibiotics out of the cell, thus rendering the antibiotics inactive (Figure 
3). These defense mechanisms become active when toxin sensors in the bacterium 
modify or detect antibiotics in the cell. The toxin sensor can trigger protein 
production that modifies or degrades the antibiotics or triggers an efflux pump to 
pump the antibiotics out of the cell. The efflux pump will only be produced when it 
is needed. 
 
   
Figure 2.  This figure is indicating bacteria actively transferring the 
resistance gene, which will lead to another bacterium becoming resistant to 
antibiotics. 
     6  6 
 
 
 
Figure 3.  The efflux pump was triggered by the toxin sensor in the 
bacterial cell to transport the antibiotics from the cell and into the external 
environment.  
 
 
 
The toxin sensor works like a light switch: it only turns on and off. When no 
antibiotics are present, the toxin sensor is off, and the efflux pump is not produced. 
However when the antibiotic concentration reaches its threshold, the toxin sensor 
recognizes the antibiotic and triggers production of the efflux pump by gene 
expression regulation. Gene expression regulation by riboswitch RNA sensors is 
dependent upon an allosteric conformational change that is triggered by binding of 
a small molecule (the antibiotic) to the mRNA. When the antibiotic is not bound, 
then the resistance gene is not produced. Thus by inactivating the sensor we can 
prevent resistance gene production can be prevented. 
     7  7 
(a) Transcription 
To get a deeper understanding of the mode of regulation we have to discuss 
the process of transcription and translation. “Transcription is the process in which 
single stranded RNA with a base sequence complementary to the template strand of 
DNA is synthesized” (7). Transcription generates several types of RNA. These 
include mRNA, tRNA, and rRNA. In bacteria one RNA polymerase catalyzes the 
synthesis of all RNAs.  
Transcription consists of three steps: initiation, elongation, and termination. 
The initiation of transcription involves the binding of RNA polymerase to a 
promoter. A promoter is a regulatory DNA sequence located upstream from the 
gene. The sigma factor recognizes promoters. They are promoter specific. RNA 
polymerase uses different sigma factors. After the sigma factor has fallen off and the 
affinity of the RNA polymerase complex has decreased for the promoter site, 
elongation can begin. During this phase the RNA polymerase converts to an active 
transcription complex as it binds numerous proteins.  Ribonucleotides are 
continuously added until a termination signal is made (Figure 4). In bacteria there 
are two types of termination, intrinsic termination also known as rho-independent 
termination, and rho-dependent termination. Intrinsic termination comes about by 
transcription of the termination sequence that consists of an inverted repeat 
sequence followed by 6-8 adenines. The terminator stem-loop directs RNA 
polymerase and will act as a roadblock to stall the polymerase (8). The RNA 
polymerase will simulate the release of the freshly made mRNA by rho-independent     8  8 
terminators (9). It is released because there are only weak A-U base pairs following 
the terminator stem. Rho-dependent termination comes about with the aid of the 
rho factor. This ATP-dependent helicase binds to a specific recognition sequence on 
the mRNA strand up stream from the terminator site and then unwinds the RNA-
DNA helix to release the mRNA and stop transcription.  
Riboswitches are RNA based control mechanisms, which can potentially 
repress active gene expression by triggering transcription or translation. 
Subinhibitory concentrations cause significant transcription modulation.  
 
 
Figure 4.  Transcription mechanism. 
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(b) Translation 
Protein synthesis is regulated by the 5 untranslated region (UTR) of the mRNA 
transcript (10).  The ribosome binding site (RBS) binds to the ribosome to set up the 
correct sequences that will initiate translation. “The RBS controls the accuracy and 
efficiency with which the translation of mRNA begins”. (11). It is called the Shine-
Dalgarno sequence.  Protein synthesis is, “the process by which the genetic message 
carried by mRNAs directs the synthesis of polypeptides with the aid of ribosomes 
and other cell constituents” (7). The translation of a genetic message into a primary 
sequence of polypeptides is done in three steps similar to that of transcription: 
initiation, elongation, and termination. Translation starts with initiation, which 
occurs once the small ribosomal subunit, binds an mRNA. The initiator tRNA base 
pairs with the initiation codon AUG on the mRNA and ends once the large ribosomal 
subunit combines with the small subunit. There are two sites for the codon-
anticodon interaction on the ribosome. One being the P (peptidyl) site and the other 
is the A (aminoacyl) site, in the elongation phase. The polypeptide is synthesized, 
based on the information received from the genetic message (or codon sequence). 
The mRNA base sequence is read in the 5 to 3 direction and the polypeptide 
sequence starts at the N-terminal and ends at the C-terminal. The elongation 
process starts when a second aminoacyl-tRNA is attached to the ribosome in the A 
site due to codon-anticodon base pairing. Peptidyl transferase catalyzes the peptide 
bonds formed. For this to occur the -amino group of the A site amino acid attacks 
the carbonyl group of the P site amino acid. Ribosomes move along the mRNA and     10  10 
the next codon enters the A site. The growing peptide chain then moves to the P site. 
This is the elongation process that is continued until a stop codon enters the A site. 
Termination occurs when the polypeptide chain is released from the ribosome. This 
process comes about because a stop codon cannot bind an aminoacyl-tRNA. Thus a 
protein releasing factor binds to the A site. The peptidyl transferase hydrolyzes the 
completed polypeptide chain and the tRNA in the P site. Translation ends as the 
ribosome releases the mRNA and dissociates into the large and small subunits 
(Figure 5).   
Transcription and translation can be modulated in many different ways in 
bacteria. Most antibiotics work as inhibitors of translation. The ribosome has 
receptors for many natural product inhibitors. All steps of translation on 
prokaryotic ribosomes are targets for specific antibiotic inhibitors (6). While this is 
true, there are very few ribosomal inhibitors of eukaryotic translation that are 
known. The difference between bacterial and eukaryotic processes has to be 
explored because the antibiotic cannot attack the host but it must attack the 
pathogen. Thus the difference between prokaryotic and eukaryotic translation have 
to be exploited so that only bacterial translation is affected. Bacterial translation is 
quite prone to mutagenis thus rendering the antibiotics useless.     11  11 
 
Figure 5.  Translation mechanism. 
 
The riboswitch is considered a new class of regulatory RNAs. What makes 
them so special is the fact that they do not require any intermediary sensory 
molecules.  They behave as small sensors of small molecules themselves. These     12  12 
natural RNA aptamers seem to control expression of numerous metabolic genes in 
bacteria and possibly in higher organisms. They are made more commonly in 
bacteria. These riboswitch aptamers are well conserved and appear not to change 
during evolution. Thus they are expected to be less prone to resistance causing 
mutagenesis.  
 
(2) How do riboswitches regulate gene expression? 
 
The expression of many genes necessary to metabolite biosynthesis or 
transport in bacteria is regulated by mRNA structures known as riboswitches. They 
are mostly found in the 5 untranslated region of the mRNA of the target gene. Genes 
that contain riboswitches code for proteins that are involved in transport or 
synthesis of molecules that are costly to produce such as thiamine pyrophosphate 
(TPP) or flavin mononucleotide (FMN). They work as feedback inhibitors. There 
have been 12 different classes of riboswitches reported (Figure 6).  
Each class of riboswitches forms a structured receptor, known as an aptamer, 
which binds to a specific fundamental metabolite without the help of a protein 
factor as well as a gene expression regulator known as the expression platform. 
Riboswitches within each class bind to the same metabolite and share highly 
conserved sequences and secondary structures. This indicates that all riboswitches 
of a given class form a common fold to recognize their cognate ligand (12). 
“Additionally, some bacterial genomes carry multiple riboswitches of the same class,     13  13 
each regulating a different operon” (12). Many antibacterial drugs can be more 
effective due to many of the same classes of riboswitches being found in numerous 
different bacterial species. 
 
 
Figure 6.  There are many classes of riboswitches. They are shown in the 
figure above. 
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Riboswitches function as sensors and are direct regulators of cellular 
metabolite concentrations because the genes regulated by them are generally 
involved in the synthesis or transport of their cognitive metabolites. They modify 
the expression of biosynthetic and transport proteins by binding to particular 
ligands. These ligands that bind to specific riboswitches are amino acids, nuclear 
bases, and sugars such as guanine, adenine, lysine, glycine, and thiamine 
pyrophosphate. The result of ligand binding is a structural change in the riboswitch, 
which affects the ability of RNA polymerase to continue the process of transcription 
elongation or the ability of the ribosome to translate an mRNA. The former affects 
gene expression through the formation of intrinsic transcription terminator 
structures. Although the transcription elongation structure of the RNA polymerase 
is stable, it is broken down by DNA termination sequences. The terminator stem-
loop, which directs RNA polymerase, will stall the polymerase by acting as a 
roadblock (8). The RNA polymerase will simulate the release of the RNA which is 
done by rho-independent terminators (9) as can be seen in Figure 4. Translation 
switches regulate expression sequestration of the ribosome-binding site.  
Riboswitches consist of two domains. One is the aptamer domain, which 
involves ligand binding. The other is the expression platform, which detects the 
changes in gene expression. Most riboswitches recognize single metabolites to 
modulate gene expression. If the metabolite is not present in the 5 untranslated 
regions when it is transcribed, the riboswitch most times will refold into a structure 
that does not interfere with the expression of the open reading frame. However if     15  15 
the metabolite is present in a high enough concentration when the 5 untranslated 
regions is transcribed, it will induce a conformational change in structure, which 
will repress the expression of the open reading frame. As stated previously this 
structure will act as a terminator of transcription or sequester to translation, which 
prevents the ribosome from binding to the mRNA and translating the open reading 
frame. 
 16 
 
New RNA Motifs Suggest an Expanded Scope for Riboswitches in Bacterial 
Genetic Control 
 
 
 
  Within mRNA there are highly structured domains that control gene 
expression and sense metabolites known as riboswitches. They have characteristics 
similar to protein genetic factors and transcription factors and modulate 
transcription or translation. “Riboswitches are versatile genetic control elements” 
that can account for why the same aptamer class in the same prokaryotic organism 
can control both transcription and translation (13). Also discovered is that mRNA 
processing can be used by riboswitches to modulate gene expression which led to 
the discovery of the first ribozyme riboswitch (13). 
 “Riboswitches form ligand-receptor interfaces with a level of structural 
complexity and selectivity that approaches that of proteins” and data provides 
“compelling evidence that riboswitches form structured receptors that are among 
the most selective of any RNA drug target” (12).  This means that one can make 
highly selective riboswitch-targeting compounds that do not bind to other cellular 
molecules. When a metabolite binds to the riboswitch it induces a conformational     17  17 
change of the mRNA. Due to the metabolite binding, the mRNA switches the 
conformation from one that is favorable to the expression of the 18 
 
encoded proteins to one that is not favorable. RNA structures are complex and 
highly specific for one particular metabolite. RNAs discriminate between and do not 
allow binding of even very closely related metabolites, because of this these 
structures can be mutated so they can recognize new metabolite targets (14). 
Metabolite binding can be a kinetically or thermodynamically directed 
process. When the rate of the metabolite binding to the RNA exceeds the rate in 
which the riboswitch is folding then the process is kinetic. On the other hand when 
the metabolite binding occurs and the riboswitch structure is more stabile 
compared to the other mRNA conformations, the process is thermodynamic (15).  
As well as RNA folding, the rate of transcription elongation by RNA polymerase 
plays a role in kinetic and thermodynamic control of riboswitches. The rate at which 
RNA polymerase synthesizes mRNA is dependent on the concentration of nucleotide 
triphosphates, Mg2+ ions, transcription factor, and the sequence of the DNA 
template. “A process that enables conformational rearrangements to occur, 
especially in the presence of Mg2+ ions that can influence the tertiary structure of an 
mRNA, could lead to more efficient ligand binding and hence, heightened gene 
expression control by the riboswitch” (15). 
Organisms use RNA in many regulatory mechanisms to control gene 
expression. The primary examples are transcription and translation in bacteria. The 
idea of these mechanisms is that an outside source that generally has to do with the 
metabolic status of the cell, controls the formation of a stem-loop RNA structure that     19  19 
will either terminate transcription too soon or sequester the Shine-Dalgarno (SD) 
sequence and prevent translation initiation (see Figure 7). 
 
 
Figure 7  Showing the secondary structure of a riboswitch. It is 
indicating the aptamer and expression platform that will form a terminator, 
antiterminator, squestor, or antisequestor. 
 
Protein factors have been implicated in the regulation of these processes. Some 
proteins control the formation of other RNA structures that act as an intrinsic 
transcription terminator or SD sequester, or even the antiterminator or 
Expression is 
OFF (not 
permitted). 
Expression 
is ON 
(permitted).     20  20 
antisequester. In many cases the leader region that binds the factor can form a third 
structure. It can form the anti-antiterminator or the anti-antisequestor. These 
enable the protein to control transcription termination or translation initiation at a 
large distance from the terminator or ribosome-binding site. Bacterial riboswitches 
repress or activate their genes depending on the configuration of the corresponding 
leader RNA sequence. If there is a change in the metabolite concentration, the 
riboswitch can control transcription termination, translation initiation, or both if the 
stem-loop structure of the terminator also serves as a sequester of the ribosome-
binding site. The riboswitch structure will be stabilized if a specific metabolite is 
bound to the conserved RNA-sensor domain. This will prevent an alternate RNA 
structure from forming which could be the terminator, sequester, antiterminator, or 
antisequester of the ribosome-binding site.  21 
 
Gene Regulation by Riboswitches 
 
 
 
  The expression of many genes in a cell constantly needs to provide the 
correct levels of RNA and protein production. Gene-control systems must be able to 
do all the same things a normal cell would be able to carry out. Therefore they need 
to be very specific, rapid, and efficient in the level of expression of many genes.  
  Riboswitches control gene expression. Based on the leader RNA sequence 
bacterial riboswitches will activate or repress gene expression. Depending on how 
the metabolite concentration changes the riboswitch controls transcription 
termination or translation initiation, perhaps both if the stem-loop structure of the 
terminator is also a sequestor of the ribosome binding site. The riboswitch structure 
is stabilized when the specific metabolite is bound to the conserved RNA-sensor. 
This will prevent the alternative structure from forming which may be an 
antiterminator, antisequester, terminator, or sequestor (16). Intrinsic terminators 
are extended stem-loop structures that allow the RNA polymerase to stop 
transcription before the coding part of the mRNA is formed. Before the metabolite 
concentration reaches its threshold, the ligand will not bind to the aptamer domain. 
This will allow formation of an antiterminator stem, which will 22 
 
allow complete transcription of the mRNA. However if the metabolite concentration 
threshold is reached, an allosteric change will occur producing the intrinsic 
terminator and preventing gene expression (17). (Offswitch). Likewise riboswitches 
may trigger transcription or translation by unfolding a terminator or unmasking the 
SD sequence (Onswitches). 
 
(3) YkkCD Riboswitch 
Efflux  pumps  are  proteins  that  transport  toxic  substrates  (including 
antibiotics) out of the cell and into the external environment. Pumps maybe specific 
to a single metabolite or can transport compounds that are different structurally. 
These are typically involved with multiple drug resistance (MDR). There are five 
classes of efflux pumps: major facilitator (MF), multidrug and toxic efflux (MATE), 
resistance-nodulation-division  (RND),  small  multidrug resistance  (SMR) and ATP 
binding cassette (ABC) (18). The ykkCD efflux pump is a part of the SMR family of 
efflux pumps (19). It is a heterodimer pump with broad ligand specification that 
includes streptomycin, ethidium bromide, etc. 
The sensor that we are studying is the ykkCD riboswitch. This sensor can be 
found in the 5' untranslated region of the ykkCD efflux pump gene. This sensor is 
specific to tetracycline and only recognizes the antibiotic tetracycline, but the 
aptamer domain binds to minocycline and anhydrotetracycline as well. The level of 
gene expression can be affected at the transcription or translation stage of protein 
production. When the antibiotic concentration reaches its threshold an allosteric     23  23 
conformational change is induced which at the transcription stage unfolds the 
terminator stem. On the other hand at the translational stage the ribosome binding 
site will be unmasked. When the Bacillus subtilus cells were grown with 
tetracycline, there was an increase in the levels of efflux pump mRNA, which 
indicates regulation at the transcription stage. Runoff transcription assays in the 
presence of tetracycline were done that indicated the riboswitch sensor is sufficient 
to increase the level of the pump mRNA (Figures 8 & 9). These assays were 
performed in vitro containing only the riboswitch and the efflux pump to verify the 
results. When the riboswitch is off, only the riboswitch is produced because the 
terminator stem stops the polymerase. However when the riboswitch is on, an 
allosteric conformational change occurs where both the riboswitch and the pump 
are produced. This will produce a longer transcript. 
  
Figure 8.  Runoff transcription is shown here.     24  24 
 
Figure 9.  The ykkCD riboswitch and tetracycline appears sufficient to 
increase pump mRNA levels thus upregulating expression if the ykkCD efflux pump. 
 
 
(4) The YkkCD Riboswitch sensor 
The riboswitch sensor has two parts. The first part is the aptamer domain, 
which specifically recognizes tetracycline. The second part is the expression 
platform that undergoes an allosteric conformational change to regulate the level of 
pump production. Also at work is the terminator stem, which acts as a roadblock for 
the polymerase. It does this by stopping the polymerase, which falls off the DNA and 
does not make any more RNA. (See Figure 10). 
     25  25 
 
Figure 10.  The predicted secondary structure of the ykkCD riboswitch. On 
the left is the aptamer and on the right is the expression platform. 
 
 
 
(a) Lock and Key Model 
   RNA aptamers of riboswitches are considered complex structures that are 
able to specifically recognize their target molecule rejecting any closely related 
compound. Their specificity rivals that of protein receptors. How is RNA capable of 
achieving such specificity? Thus we need to uncover the interaction between 
tetracycline and the sensor RNA must be determined to understand how it 
Terminator  Stem 
Distal Arm 
Central 
Bulge 
3’ Stem-loop 
5’ Stem     26  26 
specifically recognizes the antibiotic. The molecular basis of specific recognition can 
be understood using a simple lock and key model (See Figure 11). The antibiotic 
would be analogous to the key and the riboswitch to the lock. Only a perfect fit 
between the sensor and the antibiotic will trigger production of the resistance gene. 
Next, the functional groups which are important in tetracycline for recognition and 
which part of the riboswitch sensor is important for recognition must be 
determined. 
 
 
 
Figure 11.  The lock and key model is an analogy used to simplify how the ykkCD 
sensor specifically recognizes tetracycline. 
  
 
To evaluate the tetracycline-sensor RNA binding affinity, a high-throughput 
assay had to be developed. The idea behind the assay is an energy transfer between 
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two chromophores. When a fluorescing chromophore absorbs light, the energy can 
be released as light in a process known as fluorescence. If another chromophore is 
within about 100 amino acids of the first and absorbs the light at the wavelength of 
emission, the energy will likely be transferred. This is known as quenching (20) see 
Figure 12. The amount of chromophore in close enough range to quench the other is 
dependent on the amount of ligand present in the assay medium. The materials are 
placed in an aqueous medium that contains buffer, incubated, and irradiated with 
light absorbed by the molecule undergoing fluorescence. (20). The amount of ligand 
can be determined once a time interval is determined or the system has reached 
equilibrium, and the results are compared with a known standard. This system 
appears to be quick and easy; however, there are many problems that can occur and 
many pieces to resolve before the assay can be completed. The RNA has to be made 
and it has to be in its native-like conformation. The RNA needs to be pure when 
adding it to the assay, so that there is very little of anything else affecting the results. 
When the RNA is purified it is denatured and thus has to be refolded to reach its 
native-like structure. 
Mg2+ plays a significant part in the structure and function of many RNAs. It 
has been shown to stabilize the tertiary structure of RNA under conditions that only 
weakly affect the stability of the secondary structure. Mg2+ levels when increased 
enable tighter metabolite binding. This will lead to a reorganization of the binding 
pocket in certain riboswitches. Thus it is important to optimize the appropriate     28  28 
magnesium concentration and RNA refolding procedure before binding assays are 
conducted. 
 
 
 
Figure 12.  In the middle the infinite 200 plate reader to read out the 
fluorescent quenching assays. To the left is a schematic of fluorescent quenching and 
to the right is an example result. 
 
 
 
(b) Tetracycline and Riboswitch Sensor Recognition 
  To test the importance of tetracycline functional groups we tested four 
tetracycline derivatives and tetracycline. The derivatives were anhydrotetracycline, 
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doxycycline, minocycline, and oxytetracycline. Figure 13 shows how they differ 
structurally from tetracycline, the base antibiotic.  
Because tetracycline and its derivatives are fluorescent, the same high-
throughput fluorescent quenching assay can be used to find their binding affinities 
(KD value). Specifically due to the excitation and emission wavelengths being similar 
and very close in range as can be seen in Table 1, it is possible to use the same 
assays by adjusting the wavelengths on the fluorescent plate reader. This is helpful 
because it is quick and less material is required 
 
     30  30 
Figure 13.  Tetracycline and derivatives structure. Colors indicate how each 
structure is different from tetracycline. Arrows indicate if a functional group acts as 
H-bond donor, acceptor or both. 
Table 1. 
   
 
To test which part of the riboswitch is important for recognition, site 
directed mutagenesis of evolutionary conserved riboswitch regions was performed. 
The nucleotides conserved through evolution are believed to be important for 
recognition. By using multiple sequence alignment of sensor sequences from 15 
different bacterial species, the conserved nucleotides were identified. These 
invariable blocks were subjected to site-directed mutagenesis. The ability of these 
mutant sensors to recognize tetracycline was evaluated using binding assays. If the 
mutated sensor lost the ability to recognize tetracycline, the invariable block is 
important for tetracycline recognition. Figure 14 shows the multiple sequence 
alignment for 15 gram (+) bacterial species. The red areas show the invariable 
blocks conserved more than 90%. The blue areas show the invariable blocks 
conserved more than 50%. The invariable blocks marked in red which are located     31  31 
on the secondary structure of the riboswitch sensor seen in Figure 14 has the 
highest conservation and is likely to be involved in tetracycline recognition.  
 
 
 
Figure 14.  The invariable blocks in red are 90% conserved and are most likely 
involved in tetracycline recognition. 
 
 
 
 
 
 
(c) Quikchange Site-directed Mutagenesis 
Quikchange site-directed mutagenesis is used to make the ykkCD sensor mutants.  
For this procedure, PCR is the first step. The circular plasmid DNA that contains the 
wild type DNA sensor is analyzed to find one spot which is indicated by a bullet 
circle in Figure 15 the wild type DNA will be changed to the new mutated DNA. The 
process requires primers, which are designed to change the sequence (short DNA 
sequence) with the mutated sequence desired. The polymerase then synthesizes the 
plasmid DNA containing the mutated DNA sequence. Once the sequence is made, the     32  32 
wild type DNA needs to be removed. This is accomplished by adding the DpnI 
enzyme. The wild type DNA is methylated and the enzyme digests the methylated 
wild type DNA. A transformation is then required to produce more of the DNA 
sequence wanted (Figure 15).  
 
1. PCR Procedure 
To perform the PCR there are many steps to complete.To a PCR tube, 25L of 
Pfu master mix buffer,  1 L of the top primer, 1 L of the bottom primer. Add 1 L 
of the wild type DNA, 23 L of RNase free water were added. All liquids were 
centrifuged before being placed into the PCR machine, using the program 
 setting 465 lab, which has the correct time intervals for its respective temperature, 
i.e. 95 C for 1 minute. After the DNA has been made, 1 L of DpN1 enzyme was 
added to digest the wild type DNA. Once the wild type DNA has been digested the 
transformation can be completed.  
 
2. Transformation Procedure 
10L of the mutated DNA was added to 100 L of the Dh5 competent cells. 
The cells were stored on ice for 20 minutes. The cells were then heat shocked for 2 
minutes at 42 C. The cells were cooled on ice for 2 minutes. The cells were 
incubated and grown in a shaker at 37 C, 120 rpm for one hour. 900 L LB media 
was added to labeled sterile glass tubes. The 110 L of cells were transferred to the 
media in the glass tubes. After the cells were grown, the cells were transferred to     33  33 
sterile centrifuge tubes. The cells in solution were spun for 2 minutes to extract the 
cells from the media. 900 L of LB media was removed and the cells were 
resuspended in the remaining 100 L of LB media. The cells were plated on a LB 
agar and 150 g/mL ampicillin plates (Sigma, #A0166-25G).  The plate was placed 
into a 37 C incubator overnight for about 19 hours. Once the colonies were grown, 
they were inoculated in 20-40 mL of LB broth and grown overnight for about 19 
hours.     34  34 
 
Figure 15.  Quickchange PCR mechanism. 
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(e) Plasmid Prep 
Next, the plasmid prep was performed. In the procedure the mutant sensor DNA 
will be purified from the bacterial cells. The quality of plasmid DNA can be evaluated 
using an UV spectrophotometer and agarose gel electrophoresis. A traditional 
plasmid prep was begun with an overnight inoculation of harvest cells grown by 
centrifugation. The bacterial culture was spun down leaving only the cells. Next the 
lysis procedure was performed. Lysozyme solution (which degrades the cell wall), 
alkali (which punches holes in the cell membrane), and the neutralization solution 
were added. Next the extract was spun. The extract was cleaned with phenol and 
chloroform (or by column purification). The DNA was precipitated with alcohol. The 
DNA was concentrated; cells were spun to pellets and resuspended in sterile water 
or TE. 
 
1.  Five Minute Plasmid Miniprep Procedure 
A Sigma-Aldrich GenElute Five-Minute Plasmid Miniprep kit (Sigma, 
PFM 10, PFM 50, PFM 250) was used for DNA isolation according to the 
manufacture’s instructions. The culture was lysed. 40 L of constituted lysis 
reagent was added to 400 L of overnight culture in a 2 mL collection tube. It 
was mixed by rapid inversion and incubated for 2 minutes. The binding 
column was prepared. 500 µL of column prep solution was added to a 
binding column seated in a 2 mL collection tube. The solution was spun for     36  36 
10 seconds and the flow through was discarded. The DNA was bound to the 
column. 400 µL of binding solution was added to the tube and mixed by 
inversion 15 times. The roughly 780 µL of mixture was added to a pre-
washed binding column and spun for 20 seconds. The flow through was 
discarded. 700 µL of diluted wash solution was added to the column and 
spun for 20 seconds to remove impurities. The flow through was discarded. 
200 µL of diluted wash solution was added to the column and spun for 30 
seconds. The plasmid DNA was eluted from the column. The column was 
carefully transferred to a new 2 mL collection tube, 40 µL of elution solution 
was added, and the column was spun for 30 seconds. For larger volumes, the 
large volume plasmid prep was used. 
 
2.  GenElute Plasmid Midiprep Kit 
A Sigma-Aldrich GenElute Plasmid Midiprep kit (Sigma, PLD 35, 
PLD140) was used for DNA isolation of larger volumes according to the 
manufacture’s instructions. The cells were harvested overnight. 5-40 mL of 
overnight recombinant E. coli culture were spun to a pellet by centrifugation. 
The appropriate volume of recombinant E. coli culture was added to an Oak 
Ridge style tube. The solution was centrifuged at 3,000-5,000 xg for 5-10 
minutes. The entire medium supernatant was removed and discarded. Next  
the cells were resuspended in solution. The bacterial pellet was resuspended 
with 1.2 mL of resuspention solution by pipetting up and down. Then     37  37 
similarly in the miniprep, the cells were lysed. Adding 1.2 mL of the lysis 
solution lysed the resuspended cells. The solution was mixed immediately by 
gentle inversion 6-8 times until the solution becomes clear. Do not exceed 5 
minutes. Next the solution was neutralized. 1.6 mL of the neutralization/ 
binding solution was added to precipitate the cell debris. The tube was gently 
inverted 4-6 times. The cell debris was spun to a pellet by centrifuging at or 
above 15,000 xg for 10-15minutes. 
 
(f) Agarose Gel Electrophoresis 
  An agarose gel is a technique, which separates DNA by molecular weight. 
However in the process it does not denature the DNA. Since the gel does not 
denature the DNA, molecules migrate based on their charge and their shape. The 
supercoiled and circular DNA can be distinguished in this method. Also because the 
DNA is negatively charged primarily due to the phosphodiester bonds, there is no 
need to coat the DNA with a molecule that is negatively charged. This is important 
because the molecules migrate in an electric field from negative to positive. In order 
to estimate the size of the DNA based on comparison, a molecular weight marker is 
used. To see the DNA, the agarose gel is stained with ethidium bromide (EtBr). The 
EtBr fluorescent molecule chelates with DNA bases so that is can be observed. The 
EtBr that is not chelated with the DNA migrates out of the gel quickly due to its 
small size. The DNA then fluoresces under UV light because the EtBr is fluorescent. 
To run the DNA samples, 10 µL of the DNA with 2 µL of 6x loading dye was loaded     38  38 
into the wells of the gel. The machine was set to 100 V and run for at least 20 
minutes. The gel was exposed to UV light to take a picture. 
 
1.  Preparing Agarose Gel 
A cork Erlenmeyer flask is used. 1 gram of agarose was added to the 
flask. Then 100 mL of 1x tris-acetate-EDTA (TAE) buffer was added.  The 
flask and contents were microwaved for one minute or until it was 
boiling. Running cool water on the outside of the flask cooled the flask. 10 
µL of EtBr was added for staining. The contents were poured into the gel 
plate. It sat for 15 minutes to set.39 
 
(5) Preparing DNA for RNA synthesis 
 
 
 
     (a) Linearization of the DNA Protocol 
  For a 100 µL reaction mixture, = 10 µL of XbaI or BamHI restriction enzymes 
was added. 10 µL of 10x buffer 4 was added for XbaI or buffer 3 for BamHI. Then 10 
µL of 10x BSA was added to the mixture. 70-75 µL of the DNA was added for 
linearization. The mixture was placed in the water bath for 1 hour. This process was 
optimized as we found that an hour was not long enough for the process to be 
completed and the maximum amount of enzyme was necessary. At first the time was 
increased to 3 hours, but that was not a long enough time. The overnight in the 
water bath and the maximum 10% of enzyme was found to be optimal for the 
linearization (Figure 16).  40 
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Figure 16.  Linearization of Y DNA on an agarose gel. Lane 1 represents 
supercoiled (uncut) DNA; Lanes 2,4,5,6 represent linearized DNA. 
 
 
(b) Phenol Chloroform Extraction Procedure 
  For a 100 µL reaction, 100 µL of phenol chloroform (25 phenol: 24 
chloroform: 1 isoamyl alcohol) was added but we made sure to take the bottom 
layer of the mixture. The tube was vortexed for 20 seconds. The tube was spun for 2 
minutes to separate the layers. The bottom layer will be the layer of phenol 
chloroform, which was removed. Next 100 µL of chloroform was added to the tube 
and vortexed for 20 seconds to mix. Once again the tube was spun for 2 minutes to 
separate the chloroform from the desired DNA. The bottom layer was removed. 
Finally 10 µL of sodium acetate and 100 µL of isopropanol were added to the 
mixture. The tube was vortexed for 20 seconds as previously done. The tube was 
placed in the -20° C freezer for precipitation. 
     41  41 
 
(c) Plasmid Prep Precipitation Procedure 
  The plasmid DNA was spun for 30 minutes at maximum speed of ~13,500 
rpm at 4° C.  The supernatant was carefully removed. 50 µL of cold 75% ethanol was 
added. The plasmid DNA was spun at maximum speed for 5 minutes at 4° C. The 
supernatant was removed. The DNA pellet was dried using a speed vacuum for 5 
minutes. The pellet was resuspended in 50µL of 1x tris-HCl and EDTA (TE).  The 
concentration of the plasmid DNA was checked by UV spectrophotometer. An 
agarose gel was run and a picture was taken. 
 
(d) Transcription: DNA to RNA Procedure 
  The transcription has been done a few different ways. Each way appears to 
work about the same. The reason for using different methods is optimization and 
availability of materials. The first recipe for a 50µL transcription, 1µL of T7RNA 
enzyme, 12 µL of DNA as long as it adds up to be 1µg, 5µL of 10x buffer, 5µL of rNTP, 
which needs to be 0.5 µM in each reaction, and 27 µL of RNase free water were 
added. The reaction mixture then went in a water bath for 1 hour and 30minutes at 
37° C. After the transcription was complete, a urea gel was run to check that the 
transcription was complete. 
  The second method for a 50 µL reaction was done. 1 µL of 1M Tris, 5µL of 
10% T7RNA enzyme, varying volume of DNA as long as it adds up to be 1µg, 2.5µL of 
100mM DTT, 12µL of 100mM MgCl2, 0.5 µL of 1% Triton, 2.5µL of rNTP, and varying     42  42 
volume of RNase free water depending on the amount of DNA were added. The 
reaction mixture sat in the 37° C water bath for 1 hour and 30 minutes just as the 
previous method. Because the materials for this method are more readily accessible, 
it had become the dominant method for transcription. 
  The final method of transcription for a 20 µL reaction was done. 4 µL of 
linearized DNA, 10 µL of 2x buffer, 2 µL of enzyme mix, 1 µL of RNase inhibitor, and 
3 µL of RNase free water were added. The mixture was placed in to the 37° C water 
bath for 30 minutes. This was the most efficient method however the least available 
(Figure 17).  
 
 
Figure 17.  Transcription of Y DNA to RNA on a small urea gel. 
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(e) RNA Clean Up 
  Once the RNA has been made, it must be cleaned. In other words the RNA 
must be purified from salt, supercoiled and unsupercoiled DNA, polymerase, buffer, 
and RNA degradation products. These may interfere with the binding assays. There 
are many ways to clean the RNA. Multiple methods and kits have been tried to find 
the best results, which will be explained. 
 
Methods: 
(a) RNA Cleanup Kit 1 
RNeasy Mini kit (Qiagen, 74104) was used according to the manufacturer’s 
instructions. First the sample was adjusted to a volume of 100 µL with RNase 
free water. 350 µL of RLT buffer was added and mixed well. Then 250 µL of 
pure  (96-100%) ethanol was added to the diluted RNA and mixed well by 
pipetting. The sample was transferred to an RNeasy Mini Spin column and 
placed in a 2mL collection tube. The sample was centrifuged 15 seconds at 
8,000 xg (≥ 10,000 rpm).  That flow-through was discarded. 500 µL of buffer 
AE was added to the RNeasy spin column. The mixture was centrifuged for 
15 seconds at ≥ 10,000 rpm to wash the spin column membrane. The spin 
column was removed so it did not touch the flow-through. Next the RNeasy 
spin column was placed in a new 2mL collection tube and the old collection 
tube was discarded. The solution was centrifuged at full speed for 1 minute. 
The RNeasy spin column was placed in a new 1.5 mL collection tube.  30-50     44  44 
µL RNase fee water was added directly to the spin column membrane. Last 
the column was centrifuged for 1 minute at ≥ 10,000 rpm to elute the RNA. 
 
(b) RNA Cleanup/ QIAquick Nucleotide Removal Kit 
QIAquick Nucleotide Removal kit (Qiagen, 28304) was used according to the 
manufacturer’s instructions. First 5 times the volume of buffer PN was added 
to the sample. The QIAquick spin column was placed in the provided 2 mL 
collection tube. The DNA was bound to the column. The sample was added to 
the column and centrifuged for 1 minute at 6,000 rpm. Then the flow-
through was discarded. 750 µL of buffer PE was added and centrifuged for 1 
minute at 6,000 rpm. The flow-through was discarded. The sample was 
centrifuged again for 1 minute at 13,000 rpm to ensure that the PE buffer 
was gone. The column was placed in a clean 1.5 mL collection tube and 
centrifuged for 1 minute. To elute the DNA, 100 µL of buffer EB was added 
and centrifuged for 1 minute at 13,000 rpm. 
 
(c) Gel Purification 
Gel purification was the last method and most current method used to 
clean our RNA. It was the most consistent method with the best results. 
However it was also the most time consuming method. To complete this 
purification first a large urea gel was made with larger wells to load the 
sample. The gel was run for 30 minutes with the watts of minimum 35W to     45  45 
heat the gel. While the gel was running, the RNA sample was heated for 10-15 
minutes at 100° C to refold the RNA. The sample was spun for a short time. 
After the gel was done running, the wells were cleaned and the sample was 
loaded. The sample did run through the gel for 3 hours. This was done so the 
sample separated, in particular the RNA separated from the DNA, salt, and 
other impurities. Next a UV lamp was used to find the RNA band and the 
band was cut out. Sterilized tweezers were used to place the gel bits into a 
sterile syringe. The gel pieces were crushed through the syringe into a sterile 
tube with 1-4 ml of RNase free water. The RNA was extracted from the gel 
bits. The gel bits were spun down and the aqueous layer was removed into 
fresh sterilized tubes.  The liquid was froze and then vacuumed down to 100-
200 µL. Finally the sample was froze at -80° C or used as needed. 
 
 
Results: 
(a)  This method resulted in very low RNA concentration. This was most 
likely due to the molecular weight cutoff of the column. The molecular 
weight cutoff of the column is 130 nucleotides and the RNA in this 
study  is 112 nucleotides long. As a result the RNA didn’t bind well to 
the column and was likely lost in the flow-through. 
(b)  This kit is designed to remove unincorporated nucleotides and the 
polymerase from the transcription mixture. As a result it does not     46  46 
remove the DNA template or the RNA degradation products. Thus it is 
unable to provide clean enough RNA for the assays. 
(c)  As stated previously the gel purification method is the newest method 
being used. It is a relatively inexpensive way to clean the RNA, with 
readily available material that can be made when needed. It is the 
most efficient method, producing the purest RNA of the three methods 
tried. The method is time consuming but gives the best results. The 
RNA separates well from the DNA, salt, and other impurities that may 
have come from the transcription. 47 
 
Fluorescent Quenching (Binding) Assays 
 
 
 
The idea behind these assays is to find the binding affinity between the 
antibiotic and the riboswitch. It helps to determine which region or regions of the 
riboswitch are important and which functional group or groups are important for 
the antibiotic. There are three possible outcomes of the mutagenesis studies done 
by this method. The mutant can improve the recognition, which will be indicated by 
KDmutant: KDwild type < 10. The mutant can destroy recognition, KDmutant: KDwild type > 10. 
Lastly, the mutant does not affect antibiotic recognition; KDmutant is within an order 
of magnitude of KDwild type. The first two outcomes will likely hit the sensor on spots 
that are important for recognition. 
 
Method 
First all necessary buffers were made. To make the 5x buffer: 1 mL of 1M 
Tris, 2.5 mL 2M KCl, 0.5 mL 100 mM MgCl2 6 mL RNase free water were added. To 
make 10 nM tetracycline, 0.004445g of solid tetracycline was weighed and dissolved 
in 10 mL of DMSO. From this point a serial of dilutions were done until 10 nM 
concentrations is reached. After the buffers and antibiotic mixtures were made the48 
 
two solutions needed for the assays were made. One solution that contains RNA and 
one solution, which do not were made. For the RNA containing solutions, 10 µL of 
the 5x buffer, 5 µL of the tetracycline or derivative mixture, 25-35 µL of RNA, 1 µL of 
RNase inhibitor, and the rest is RNase free water were added to obtain a 50 µL 
solution. For the no RNA containing solution, 130 µL of the 5x reaction buffer, 65 µL 
of the 10 nM tetracycline or derivative mixture, and 455 µL of RNase free water 
were added together. Once all appropriate mixtures were made, 50 µL of the no RNA 
containing solution was added to each well. 50 µL of the RNA containing solution 
was taken and resuspended in the first well. 50 µL of that solution was added and 
resuspended in well 2; this was continued until well 11 and the last 50 µL of 
solution was thrown out. Finally the plate was covered with parafilm, covered with 
foil, and incubated for a minimum of 3 days to allow the reaction to occur. 
The binding assays were read out. Use the I-control 1.6 program to control 
the infinite 200 plate reader and measure fluorescence of tetracycline and the 
derivatives. The appropriate excitation and emission wavelength, integration time, 
and number of flashes were chosen. The appropriate concentrations and fluorescent 
values were calculated and graphed using Graph Pad Prism. The KD values were 
recorded. 
 
Results 
  The KD values of the eleven original mutants, four new mutants, tetracycline, 
and four commercially available derivatives were reviewed (Figure 18). The more     49  49 
interesting results were any of those that changed the KD value more than one order 
of magnitude within a 20% error (see Table 2). An order of magnitude change in KD 
corresponds to about 1 kcal/mol in binding energy – roughly the energy of a H-
bond. Any less of a change cannot be easily interpreted at the molecular level. 
According to Krystal Roark, there were three mutations in the original set of 
mutants, which were made on the central bulge in the secondary structure that 
cause the largest increase in magnitude of the KD value. These were mutants 4, 8, 
and 10. Similarly in the second set of mutants which were tested, mutant 2 found in 
the same area became nonbinding (Figure 19). While mutant 7 was not in the same 
area it is located on the terminator stem of the expression platform, and it also did 
not bind. This particular area of the secondary structure has not been explored 
much, but also may be important. If this region of the RNA is altered it may cause the 
riboswitch structure to fold into an alternate structure that is not competent to 
tetracycline binding. These areas are believed to be important for tetracycline 
recognition and when changed or deleted likely cause a different structure 
formation that does not recognize tetracycline. 
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Figure 18. Binding mutants mapped to the secondary structure of the riboswitch 
aptamer domain.  
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Figure 19. Nonbinding mutants mapped to the secondary structure of the ykkCD 
riboswitch. Nonbinding mutants appear to cluster on the central bulge of the 
riboswitch indicating a site for tetracycline binding.  
 
 
  Because it is known that the riboswitch sensor does recognize tetracycline, 
which functional group(s) of tetracycline are important can be determined by 
testing tetracycline derivatives. Several binding assays were performed, which gave 
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some unexpected results. In addition to tetracycline, minocycline, and possibly 
anhydrotetracycline, bind to the riboswitch. Minocycline when bound to the 
riboswitch caused a 10-fold increase in the KD value. Anhydrotetracycline appears to 
bind, however more binding assays must be completed to be sure (Figure 20). From 
these results the lower side of the tetracycline structure is not as important to 
recognition, because minocycline changes that area significantly and binding was 
still retained albeit weakened. Both anhydrotetracycline and minocycline switches 
the carbonyl and hydroxyl groups on rings B and C. As anhydrotetracycline retained 
wild-type-like binding this change does not interfere with recognition. There are 
two possible explanations: (1) interactions with these functional groups are not 
energetically significant or (2) both functional groups act as H-bond acceptors and 
thus switching them does not prevent recognition.  Noteworthy to mention that 
anhydrotetracycline changes ring B to an aromatic ring thus changing the overall 
shape and flexibility of the molecule but does not appear to have a significant effect 
on binding. Overall shape and flexibility often has a role in how a molecule accesses 
the binding site or whether it can access it at all. As riboswitches often fold around 
their ligands (binding site is created upon binding), flexibility might not be a 
significant issue.  
 
Oxytetracycline and doxycycline both appear not to bind. This result was 
most surprising, because these two derivatives were the most similar to tetracycline 
(Figure 20). Both of these derivatives alter the upper face of tetracycline. The major     54  54 
difference between them and tetracycline is the addition of a hydroxyl group 
(circled) to ring C, which must affect the ability for recognition. This is likely due to 
either steric hindrance or hydrogen bonding to the tertiary amine that could act as a 
hydrogen bond acceptor. Testing a derivative with a methyl group attached to ring C 
might allow these two alternatives to be distinguished, but such derivative a is not 
commercially available. A hydroxyl group is also removed from ring B in 
doxycycline (boxed), but this modification is also present with anhydrotetracycline 
and it did not change the binding affinity and hence was deemed not significant. 
 
Derivatives that retained binding 
 
Derivatives that failed to bind 
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Figure 20. Tetracycline derivatives tested. Double arrows show a functional group 
that can be both H-bond acceptor and donor whereas single arrows function groups 
that act as H-bond acceptors. 
Discussion 
  All assays need to be repeated using the new protocol. There were many 
alterations to the protocols to ensure that the binding affinities were most 
accurately determined. Purification was done on a small gel instead of a large urea 
gel. This was done to prevent the RNA from being lost or smeared as can be seen in 
Figure 30. Doing gel purification on a small gel provided a clean enough sample for 
the assays and reduced purification time from one day to a few hours. Considering 
the large number of mutants that need testing this time reduction is very significant. 
The original incubation period was 2 days; however, the assay results were better 
read when the incubation period was a minimum of 3 days. Because binding affinity 
is equilibrium dissociation constant it is essential that equilibrium is reached before 
the assays are read. This is determined via a trial and error process. Binding assays 
are read 30 minutes, 6 hours, overnight and few days past setup. The incubation 
time that gives the most consistent and tightest binding (smallest KD value) is used 
in further characterizations. A shorter incubation time thus may result in the 
determination of a weaker apparent KD value.  Also included was RNase inhibitor to 
A  B  C  D  A  B  C       D     56  56 
prevent degradation of the RNA when the mixture was in the refrigerator for an 
extended length of time. 
  Some conclusions can be made regarding Krystal Roark’s mutants, which 
were tested by her, Laura Edwards and in this study. Also a few conclusions may be 
determined on the new set of mutants as well as the tetracycline derivatives. All of 
Krystal Roark’s mutants except 8 and 10 appear to be binding. Mutant 2 might have 
a 10-fold reduction in the KD. Mutants 8 and 10 appear to not bind to the RNA under 
the assay conditions, but as it was only possible to go up to 2.0x10-6M RNA 
concentration (which is a rather high concentration considering a macromolecule) it 
is more accurately said that binding affinity is greater than about 500 nM, which is a 
significant decrease (50fold). The binding assays show that the KD had the largest 
change when the mutations were made on the right side of the aptamer between 
nucleotides 41 and 50 (Figure 19). 
 
(a) Development of a New Assay Protocol to Determine Binding Affinity of Loose 
Binder Mutants 
 
The next step is to perform additional assays with the new protocol and to 
accurately determine the binding affinity of mutants that bind weakly to 
tetracycline. The problem with using this assay to determine binding affinity of 
mutants with a high KD value (loose binding) is that it requires a lot of RNA. The 
RNA concentration needs to be at least 10x the KD value. If the KD is about 100 nM     57  57 
the RNA has to be 1 µM, which is difficult to make. The binding affinity of mutants 
with a low KD value (tight binding) can be easily determined with this assay, because 
it requires less RNA: if the KD=1-10nM it is sufficient to use a few 100nM maximum 
RNA concentration. Due to the easiness of the fluorescent quenching assays and its 
high throughput nature it will continue to be used for initial screening and to 
determine binding affinity of mutants that bind well to tetracycline. To determine 
binding affinity of weak binders a few different options are available. 
Fluorescent energy transfer can be used, which involves having donor and 
acceptor fluorephores. The donor emission will overlap with the acceptor excitation. 
If binding occurs, the donor will excite the acceptor. The RNA will be labeled with 
Rhodamine and act as the acceptor. The excitation will overlap with the tetracycline 
emission, which is acting as the donor. In this assay the RNA can be used at limiting 
concentrations while titrating in tetracycline. This will allow the use of less RNA to 
be needed, but more tetracycline, which is more readily available.  This assay is still 
amenable to high throughput setup, but requires very high levels of incorporation of 
rhodamine fluorophore into the RNA. As the riboswitch RNA is too large for in vitro 
synthesis of labeled RNA (it is typically available for only up to 50 nucleotides), 
labeled RNA has to be created using in vitro transcription utilizing labeled 
nucleotides or enzymatic end labeling of RNA (phosphatase treatment to remove 
the terminal phosphate and kinase treatment using labeled nucleotide and in vitro 
transcribed RNA to introduce the fluorophore). These methods often do not provide     58  58 
high enough incorporation of fluorophore label. This method was tried but 
unfortunately sufficient label incorporation was not achieved. 
Another option is to use microcalorimetry. In this method the heat capacity 
of binding would have to be determined to find the KD value. Unfortunately the 
calorimeter in the department in not suited for biochemical usage (requires too 
much material) and thus microcalorimetry is not a feasible method, unless new 
equipment is acquired. 
The last option is to use a method that is not solution based. This would 
provide the added advantage of measuring binding affinities in a fundamentally 
different way that would provide a nice control. Krystal Roark and Alysa Frank 
developed nuclease protection assays that could be used to measure binding affinity 
of weak binders and to recheck the binding affinity of the wild type RNA as a 
control. In this assay the 5 end of the RNA is labeled. The RNA is then subjected to 
nuclease cleavage without tetracycline and with increasing amounts of tetracycline. 
Then cleavage products are resolved on a denaturing gel. The cleavage patterns are 
different in the presence of tetracycline as tetracycline binds to the RNA and 
protects nucleotides from cleavage by the nuclease. As the tetracycline is added 
gradually the pattern equivalently would change allowing the determination of the 
KD value. Even though this assay is low throughput it would only need to be used for 
the new mutants making these experiments manageable.     59  59 
Thus the best assay for future studies is using fluorescent quenching for 
initial screening and to determine binding affinities of tight binders and using 
nuclease protection assays to determine the binding affinity of lose bindings. 60 
 
Analysis of Tetracycline Analogues and Sensor Mutants In Vivo 
 
 
 
  It is necessary to compare the results of the fluorescent quenching assays, 
which is an in vitro study with in vivo data. In case of in vitro binding assays accurate 
results can be obtained about the binding affinity, but since cellular factors needed 
for transcription and translation are not present these assays test binding only and 
not how a given nucleotide or functional group contributes to the overall function of 
the riboswitch. A mutant/derivative that does not bind to tetracycline is not 
expected to be functional in vivo either, but a mutant/derivative that retains binding 
may be inactive in vivo due to interference with transcription or translation. Recall 
that the ykkCD riboswitch has been hypothesized to specifically recognize 
tetracycline and undergo a conformational change. This triggers production of the 
ykkCD efflux pump that in turn removes tetracycline toxic to the cell. To test how 
tetracycline derivatives and conserved riboswitch nucleotides contribute to 
riboswitch function in vivo we set up two different procedures. (1) To evaluate the 
amount of ykkCD pump mRNA Bacillus Subtilis cells will be grown in the presence 
and absence of tetracycline and its derivatives, and ykkCD pump mRNA levels will 
be quantified using quantitative real-time PCR. Nick Frecker in our lab is currently 61 
 
testing tetracycline derivatives for this purpose. This method did not require 
cloning or alteration of B Subtilis genome but uses the assumption that mRNA levels 
correlate well with protein levels, which is not always the case. (2) Thus the amount 
of ykkCD pump protein produced in the presence of tetracycline derivatives also 
will be quantified. However quantifying the level of a particular protein in the cell is 
difficult in the absence of a good antibody against the protein. Thus a construct was 
created where the riboswitch regulates the expression of the -galactosidase gene in 
a shuffle vector that works both in Gramm negative (E Coli) and Gramm positive 
bacteria (B Subtilis).  The “shuffle” nature of this construct allowed cloning to be 
done in E Coli where it is much more easily done and assays to be conducted in B. 
subtilus. This construct is not designed to replace the ykkCD efflux pump in B Subtilis 
genome (if the efflux pump were removed, cells would be expected to die in the 
presence of high tetracycline concentrations); it is designed to replace the 
nonessential Amy gene in Bacillus thus the construct is replicated with the Bacillus 
genome (Figure 21). Bacillus cells will be grown with tetracycline and its derivatives 
and the - galactosidase enzymatic activity will be measured using a colorimetric 
assay to evaluate the amount of protein production. This is a widely used technique 
to determine regulation of an essential gene. In case of derivatives that failed to bind 
tetracycline we expect low pump mRNA levels and low -galactosidase production. 
In case of derivatives that retained binding an increase in pump mRNA levels and 
high -galactosidase activity is expected. These expectations are consistent with the     62  62 
hypothesis where the riboswitch recognizes tetracycline and triggers efflux pump 
production that in turn removes the toxic molecule allowing survival of the cells.  
 
 
Figure 21  Quantifying protein levels in vivo.
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Appendix 
 
 
 
 
Figure A.1 & A2 Mutant 1 binding assays. 
 
mutant 1
0.0 0.2 0.4 0.6 0.8 1.0
0.00
0.05
0.10
0.15
0.20
0.25
KD=0.2098 (uM)
[RNA] (uM)

F
/

F
m
a
x
Mutant 1
0.0 0.5 1.0 1.5 2.0
0.0
0.5
1.0
1.5
KD= 0.01338 (uM)
[RNA] (uM)

F
/

F
m
a
x64 
 
 
 
 
Figure A.3 Mutant 2 binding assay. 
 
 
Figure A.4 Mutant 2 binding assay. 
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Figure A.5 Mutant 2 binding assay. 
 
 
 
 
 
 
Figure A.6 Mutant 3 binding assay. 
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Figure A.7 Mutant 3 binding assay. 
 
 
 
 
Figure A.8 Mutant 7 binding assay. 
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Figure A.9 Mutant 7 binding assay. 
 
 
 
 
Figure A.10 Mutant 7 binding assay. 
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Mutant 
code 
Primer 
seqeunceas  Bases  Sequence 
Molecular 
Weight 
Tm (50mM NaCl) 
C 
1  1top  41  GTC AAT TGA CAT GGA CTG GTG GGA GAG AAA ACA CAT ACG CG  12756.3  80.15833659 
1  1bottom  41  CGC GTA TGT GTT TTC TCT CCC ACC AGT CCA TGT CAA TTG AC  12453.1  80.15833659 
2  2top  38  TGT AAA GTT TTC TAT TCC GCA TGT CAA TTG ACA TGG AC  11657.6  70.94650526 
2  2bottom  38  GTC CAT GTC AAT TGA CAT GCG GAA TAG AAA ACT TTA CA  11693.7  70.94650526 
3  3top  45  GTA AAG TTT TCT ACC CTT CCG CAT GTC AAT TGA CAT GGA CTG GTC  13777  78.05555556 
3  3bottom  45  GAC CAG TCC ATG TCA ATT GAC ATG CGG AAG GGT AGA AAA CTT TAC  13902.1  78.05555556 
4  4top  45  TGT AAA GGG GGC TAG GGT TCC GCA TGT CAA TTG ACA TGG ACT GGT  14012.1  78.56666667 
4  4bottom  45  ACC AGT CCA TGT CAA TTG ACA TGC GGA ACC CTA GCC CCC TTT ACA  13669.9  78.56666667 
5  5top  45  ATT GAC ATG GAC TGG TCC GTC TTT TGA CAT ACG CGT AAA TAG AAG  13899.1  63.81111111 
5  5bottom  45  CTT CTA TTT ACG CGT ATG TCA AAA GAC GGA CCA GTC CAT GTC AAT  13779  63.81111111 
6  6top  33  CGC ATA TGC ACA CGG TCC GAA AAA AGC CCG GGA  10150.6  63.43939394 
6  6bottom  33  TCC CGG GCT TTT TTC GGA CCG TGT GCA TAT GCG  10118.6  63.43939394 
7  7top  24  CGG AGG GAA AAA AGC GGC GGA GAG  7575  66.5 
7  7bottom  24  CTC TCC GCC GCT TTT TTC CCT CCG  7133.6  66.5 
 
 Table 2.  Primer sequences for second set of mutations. 
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Mutant  Trial 1  Trial 2  Trial 3  Trial 4  Trial 5  Trial 6  Trial 7  Trial 8  Trial 9  Trial 10 
1.  25.000  20.000  9.900  83.770                   
2.  1.822  31.320  10.760  23.000  39.49  31.32  10.76  1.820       
3.  3.464  3.447  1.244     11.00  12.00  1.24  1.059  3.4  3.4 
4.                               
5.  6.510  1.362  2.100  2.200  1.00  0.95  2.80  1.360       
6.  68.850  26.830  267.410  8.240  95.26                
7.  3.563  5.350  8.356  5.356  8.10                
8.                               
9.  4.456  7.202  4.000  2.480  4.40  7.20             
10.                               
11.  248.000*  9.900  2.480  6.700  5.20  3.40             
                                
 
Table 3.  Krystal Roark Mutant’s KD Values 
 
 
Mutants  Trial 1  Trial 2  Trial 3 
1.  0.2098  0.01338  0.324 
2.          
3.  40.8400  38.47000    
4.          
5.          
6.          
7.          
 
Table 4.  Delores Mutant’s KD value70 
 
 
 
 
Figure A. 11 Tetracycline binding assay 
 
 
 
 
Figure A. 12 Tetracycline binding assay 
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Figure A. 13 Tetracycline binding assay 
 
 
 
 
 
 
Figure A. 14 Tetracycline binding assay 
 
 
Tetracycline
0.0 0.2 0.4 0.6
0.0
0.5
1.0
1.5 KD= 0.01541 (uM)
[RNA] (uM)

F
/

F
m
a
x
Tetracycline
0 2 4 6 8
0.0
0.5
1.0
1.5 KD= 1.157 (uM)
[RNA] (uM)

F
/

F
m
a
x    72  72 
 
 
Figure A. 15 Tetracycline binding assay 
 
 
 
 
Figure A. 16 Tetracycline binding assay 
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Figure A. 17 Tetracycline binding assay 
 
 
 
 
 
Figure A. 18 Minocycline binding assay 
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Figure A. 19 Minocycline binding assay 
 
 
 
 
 
Figure A. 20 Minocycline binding assay 
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Figure A. 21 Minocycline binding assay 
 
 
 
 
Figure A. 22 Minocycline binding assay 
 
Minocycline @ 48 hrs
0 1 2 3 4
0.0
0.5
1.0
1.5
KD= 0.3160 (uM)
[RNA] (uM)

F
/

F
m
a
x
Mino (C)
0 1 2 3 4
0.0
0.5
1.0
1.5
KD= 0.1172 (uM)
[RNA] (uM)

F
/

F
m
a
x    76  76 
 
 
Figure A. 23 Minocycline binding assay 
 
 
 
 
 
Figure A. 24 Minocycline binding assay 
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Figure A. 25 Minocycline binding assay 
 
 
 
 
Figure A. 26 Anhydotetracycline binding assay 
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Figure A. 27 Anhydotetracycline binding assay 
 
 
 
Figure A. 28 Anhydotetracycline binding assay 
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Figure A. 29 Anhydotetracycline binding assay 
 
 
 
 
 
Figure A. 30 Anhydotetracycline binding assay 
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Figure A. 31 Oxytetracycline binding assay 
 
 
 
 
Figure A. 32 Oxytetracycline binding assay 
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Figure A. 33 Oxytetracycline binding assay 
 
 
 
Figure A. 34 Oxytetracycline binding assay 
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Figure A. 35 Doxycycline binding assay 
 
 
 
 
 
 
Figure A. 36 Doxycycline binding assay 
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Figure A. 37  Gel purification exemplifying the RNA being smeared across the large 
urea gel. 
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